Peptide Liraglutide Research

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.

Alansari, Amal Omar · 2025

Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs..

Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.

Alfehaid, Lama · 2025

Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports..

Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration.

Alluri, Amruth A · 2025

In-depth analysis of liraglutide cardiovascular benefits in type 2 diabetes examines the mechanisms and evidence supporting cardiac protection through GLP-1 receptor activation..

Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.

An, Xuedong · 2025

Analysis of GLP-1 receptor agonist effects on cancer outcomes examines whether these metabolic drugs influence cancer risk, progression, or mortality..

Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.

Punthakee, Zubin · 2024

During the 16-week intervention, participants achieved significantly lower HbA1c (40 vs 51 mmol/mol, p < 0.0001) and lost more weight (3.3% vs 1.9%, p = 0.02) compared to controls. After stopping all glucose-lowering drugs, there was a 37% lower hazard of diabetes relapse in the intervention group (HR 0.63, 95% CI 0.45-0.88, p = 0.007).

Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.

Raza, Fatima Ali · 2024

GLP-1 receptor agonists work by mimicking the natural gut hormone GLP-1, which reduces appetite and slows stomach emptying.

Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.

Schoretsanitis, Georgios · 2024

Significant disproportionality was detected for semaglutide-associated suicidal ideation (ROR 1.45, 95% CI 1.18-1.77).

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

Xu, Yuan-Yuan · 2024

Liraglutide significantly reduced BMI (MD −1.06), triglycerides (MD −0.35 mmol/L), visceral adipose tissue (MD −21.06 cm²), and subcutaneous adipose tissue (MD −20.53 cm²) in T2DM patients with NAFLD across 12 studies..

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.

Caparrotta, Thomas M · 2021

Across 200,148 participants and 396,457 person-years, GLP-1 RAs showed cardiovascular safety with potential MACE benefit for liraglutide (PE range 0.53-0.95) and no association with pancreatitis, pancreatic cancer, breast cancer, or hypoglycemia..

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.

Patel, Kershaw V · 2020

GLP-1 RAs (liraglutide, semaglutide, albiglutide, dulaglutide) reduce MACE in T2DM patients with CV disease, while DPP-4 inhibitors show CV safety but no MACE benefit, with saxagliptin increasing HF risk..

Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.

Al-Moussally, Feras · 2025

GLP-1 RA use associated with reduced progression to liver transplant in NAFLD/NASH patients, supporting hepatoprotective benefits of these peptide drugs..

Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).

Al-Najim, Werd · 2025

Different lifestyle approaches combined with liraglutide produced varying outcomes, identifying optimal diet and exercise strategies for maximizing GLP-1 drug benefits..

A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.

Amirthalingam, Palanisamy · 2025

Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems..

Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.

Apperley, Louise · 2025

Liraglutide treatment improved glycemic dysregulation and body composition, demonstrating comprehensive metabolic benefits of GLP-1 receptor activation..

The effect of obesity pharmacotherapy on body composition, including muscle mass.

Argyrakopoulou, Georgia · 2025

Review of obesity pharmacotherapy effects on body composition examines how GLP-1 and related drugs affect muscle mass, fat distribution, and bone density during weight loss..

Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.

Arrowaili, Arief · 2025

Comprehensive review of GLP-1 drug efficacy and safety for weight management covers semaglutide, liraglutide, and emerging agents with real-world outcome data..

A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.

Barrett, Rosealeen · 2025

Ireland's Managed Access Protocol (MAP) for liraglutide (Saxenda) approved 52.2% of the 7,927 physician applications submitted in its first year.

Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.

Ostrominski, John W · 2025

Only 1.4% of the 1.1 million patients eligible for anti-obesity medications were actually prescribed them..

Effects of weight-loss interventions on bone health in people living with obesity.

Paccou, Julien · 2025

All weight-loss interventions increase bone turnover; bariatric surgery is worst for bone health.

SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.

Ramírez-Rincón, Alex · 2024

After approximately 26 weeks on IDegLira: - HbA1c decreased by 1.3% (from 9.1% to 7.8%, p < 0.0001) - Body weight decreased by 1 kg (from 76.1 to 75.1 kg, p < 0.0001) - No severe hypoglycemic events observed - Mean final IDegLira dose: 21.3 units These results were achieved in patients who had previously been on basal insulin (with or without oral diabetes drugs) and were not reaching their blood sugar targets.

Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.

Reddiar, Sanjeevini Babu · 2024

After subcutaneous injection in rats: - Liraglutide: apparent half-life 9.1 hours, delayed peak plasma levels, bioavailability ~10% - Exenatide: half-life ~1 hour, bioavailability ~100% Lymphatic uptake was low for both peptides (<0.5% of dose), though lymph-to-plasma concentration ratios exceeded 1 at several early timepoints, suggesting some direct lymph uptake.

Long-Term Assessment of Weight Loss Medications in a Veteran Population.

Rodriguez, Allison D · 2024

Semaglutide and phentermine/topiramate showed the most consistent long-term weight loss among veterans, with data extending up to 48 months..

Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.

Ruggiero, Rosanna · 2024

Disproportionality analysis of the European Pharmacovigilance database found no elevated signal for suicidal events with GLP-1 receptor agonists as a class..

Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes.

Shao, Wei · 2024

Liraglutide added to metformin significantly improved SBP, DBP, BMI, waist-hip ratio, glycolipid metabolism indices, and microinflammatory markers compared to metformin alone over 12 weeks (P<0.05).

The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.

Shen, Yuanyuan · 2024

Twelve weeks of liraglutide (1.8mg) in post-bariatric patients with persistent obesity produced 11.6% total weight loss versus 4.9% in controls, with an estimated treatment difference of 6.6% and improved metabolic outcomes..

Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.

Tonon, Carolina R · 2024

Liraglutide pretreatment (0.6 mg/kg daily for 2 weeks) did not improve any echocardiographic, functional, or molecular measure of doxorubicin-induced acute cardiotoxicity in rats..

Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet.

Touceda, Vanessa · 2024

Liraglutide restored healthy fat tissue characteristics in obese mice — smaller adipocytes, more blood vessels, higher MMP-9 activity, less fibrosis, and tubular mitochondrial morphology..

Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.

Walczuk, Samantha · 2024

Real-world weight loss with GLP-1RAs (semaglutide, liraglutide) and other weight management medications at 37 VA centers was smaller than clinical trials, with higher discontinuation rates and barriers including drug shortages..

Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study.

Welling, Mila S · 2024

Liraglutide 3 mg produced median weight loss of 4.7% (MCGO) and 5.2% (HSGO) after 12 weeks at maximum dose, with significant improvements in appetite, fat mass, fasting glucose, and HbA1c in adults with genetic obesity..

Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.

Xiong, Wen · 2024

Liraglutide + standard therapy achieved 97.6% effectiveness vs 78.6% for standard therapy alone, with significantly better blood glucose control, kidney function (Scr, BUN, 24h-UPor), renal fibrosis reduction, and immunoglobulin levels in 84 T2DM patients..

Laser Acupuncture versus Liraglutide in Treatment of Obesity: A Multi-Institutional Retrospective Cohort Study.

Yu, Wen-Lin · 2024

Laser acupuncture users lost an average of 5.82 kg versus 2.38 kg with liraglutide over 180 days, with the difference remaining significant after adjusting for baseline differences..

Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.

Zhang, Qian · 2024

Liraglutide directly binds Myo1c at arginine 93, enhances Myo1c/Dock5 interaction to promote keratinocyte proliferation, migration, and adhesion.

Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.

Zhao, Min · 2024

Liraglutide improved follicle development and reduced PCOS phenotype in rats by inhibiting NLRP3 inflammasome activation and pyroptosis in ovarian tissue..

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.

Quast, Daniel R · 2021

Both GLP-1 receptor agonists produced comparable effects on: - Macronutrient and energy intake (equally reduced) - Body weight loss - Appetite reduction The key mechanistic finding was that weight loss and appetite reduction were NOT related to delayed gastric emptying or GI side effects (p > 0.05 for both).

Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.

Morieri, Mario Luca · 2020

Dulaglutide reduced HbA1c 0.24% more than liraglutide in real-world clinical practice (p=0.003), confirmed by meta-analysis of observational studies..

Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.

Nohara, Hirofumi · 2020

GLP-1 receptor agonists upregulate mucin expression in airways via p38 MAPK, exacerbating emphysematous phenotypes in obstructive lung disease models..

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.

Alali, Saleh · 2025

Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles..

The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.

Albanna, Adel Ali · 2025

Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms..

Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.

Ali, Dina A · 2025

Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and antioxidant pathway modulation, adding chemo-cardioprotection to GLP-1 benefits..

New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.

Alshehri, Fahad S · 2025

Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease..

The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.

Arslan, Huseyin Emre · 2025

Liraglutide protected against indomethacin-induced gastric damage in a preclinical model, adding gastroprotection to GLP-1 drug benefits through anti-inflammatory mechanisms..

Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.

Ouyang, Yuqin · 2025

Prior metabolic surgery was associated with a 6.78x higher odds of poor response to liraglutide for weight loss..

The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.

Ozatik, Fikriye Yasemin · 2025

Liraglutide, especially at weekly dosing, reduced cisplatin-induced neuropathic pain, motor impairment, and nerve tissue damage in rats..

A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.

Pandey, Ajay · 2025

Multiple nanocarrier platforms (polymeric, lipid-based, and hybrid systems) have demonstrated improved liraglutide stability, protection from degradation, and enhanced bioavailability in preclinical studies..

Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.

Pușcașu, Ciprian · 2024

Among the novel agents studied in animal models, liraglutide showed neuroprotective and anti-inflammatory effects against vincristine-induced nerve damage.

Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.

Ramos Belinchón, Clara · 2024

Sixteen obese patients with IBD (9 Crohn's disease, 7 ulcerative colitis) received semaglutide 1.0 mg or liraglutide 3.0 mg for obesity.

Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.

Rodrigo, Natassia · 2024

Preconception weight loss through either diet modification or liraglutide treatment improved maternal kidney outcomes in late gestation in a mouse model of obesity..

Recommendation for Clarifying FDA Policy in Evaluating "Sameness" of Higher Order Structure for Generic Peptide Therapeutics.

Rogers-Crovak, Jessica A · 2024

Current FDA guidance for evaluating generic peptide drug sameness needs clarification on higher order structure assessment to ensure generic peptide drugs are safe and effective..

Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.

Rossetti, Camila Lüdke · 2024

Liraglutide prevented body weight gain, fat mass accumulation, and glucose intolerance in ovariectomized rats, a model of post-menopausal metabolic changes..

Reactivity of N terminal histidine of peptides towards excipients/impurity of excipients: A case study of liraglutide excipient compatibility study.

Sheikh, Azahar R · 2024

N-terminal histidine of liraglutide reacts with formaldehyde impurities in excipients and PLGA degradation products, forming imidazopyrimidine, glycolyl, and lactolyl interaction products..

Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway.

Shi, Lili · 2024

Liraglutide protected endothelial cells from high glucose-induced apoptosis, oxidative stress, inflammasome activation, and pyroptosis by regulating the TRIB3/NF-κB/IκB-α signaling pathway..

Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.

Trakoonsenathong, Ronnakrit · 2024

Liraglutide suppressed CCA cell migration and reduced xenograft tumor volumes by inhibiting EMT and Akt/STAT3 phosphorylation, despite GLP-1R expression being associated with poorer histological grade..

Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.

Wang, Na · 2024

Liraglutide reduces bone marrow fat accumulation in diabetic rats by suppressing miR-150-5p expression, which upregulates GDF11 — a novel mechanism explaining the peptide drug's bone-protective effects..

Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.

Wu, Zongyi · 2024

Across 17 animal studies, liraglutide improved bone imaging parameters, bone pathology, and bone maximum load while favorably altering bone metabolism markers, working through Wnt, AMPK/PGC1α, and OPG/RANKL/RANK pathways..

Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.

Wunderlich, Margit · 2024

Colonization with H.

Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.

Xuan, Yingli · 2024

Liraglutide (0.6 mg/kg for 12 weeks) protected against HFD-induced kidney injury by reducing serum lipids, improving kidney function markers, reversing kidney pathology, and inhibiting the CaMKKβ/AMPK signaling pathway.

Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.

Yi, Bo · 2024

Liraglutide improved gut microbiota diversity (increased Simpson index, P=0.035), boosted beneficial bacteria like Clostridium and Oscillospira, increased serum L-5-Oxoproline, and reduced ectopic lipid deposition in kidney tubules through SREBP1/FAS pathway suppression..

An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.

Zenno, Anna · 2024

Liraglutide produced a 4.3% BMI reduction (p<0.001) in 34 adolescents with persistent obesity after sleeve gastrectomy, with significant improvements in fasting glucose and HbA1c and 91% study completion..

Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.

Zhang, Xianyu · 2024

Liraglutide reduced RAGE expression, suppressed IL-6/IL-12/TNF-α, decreased MMP-1/-3/-13 and ADAMTS-4/-5, preserved aggrecan and collagen II, and reduced chondrocyte apoptosis via GLP-1R activation, with all effects reversed by GLP-1R blockade..

The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.

Zhong, Shuai · 2024

Liraglutide activated the Sirtuin-1 pathway in osteoblasts, protecting them from oxidative stress and promoting bone cell survival and function..

Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.

Ziebarth, Jeferson · 2024

Zein/Eudragit-chitosan nanoparticles protected liraglutide from gastric degradation, provided sustained oral delivery, and achieved effective glycemic control in animal models..

Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.

Park, Jeayoung · 2023

This meta-analysis of 24 randomized controlled trials (3,377 patients) found that GLP-1 analogs — particularly liraglutide — provide meaningful benefits when added to insulin therapy in type 1 diabetes.